Lion’s Mane
Lion's Mane (Hericium erinaceus) is an NGF-upregulating medicinal mushroom with one washout-arm RCT (Mori 2009, MCI n=30, 3 g/day for 16 weeks, Cohen's d ~0.5-0.7) showing benefits that reverted 4 weeks after cessation. Four total small human RCTs; a 25,000-member r/LionsManeRecovery signal keeps safety unsettled.
Lion’s Mane scored 6.5 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Adaptogen / Herbal → Functional Mushroom.
What It Is
Type: Medicinal mushroom (Hericium erinaceus; fruiting body or mycelium extract).
Lion's Mane (Hericium erinaceus) is an edible medicinal mushroom with a shaggy, pom-pom-like fruiting body native to North America, Europe, and East Asia. It has been consumed as food and medicine for centuries in Chinese (Houtou), Japanese (Yamabushitake), and Korean traditions, where it was historically used for "stomach weakness" and what the Song Dynasty pharmacopoeia called "lion-roar disease," possibly a dementia-like presentation.
Two chemically distinct bioactive families drive the nootropic reputation. Hericenones A through H live in the fruiting body, are lipophilic, and activate TrkA to stimulate Nerve Growth Factor (NGF) synthesis peripherally. Erinacines A through K concentrate in the mycelium, and erinacine A uniquely crosses the blood-brain barrier in rodent models to drive hippocampal neurogenesis through the BMP pathway. Both converge on NGF, BDNF, cholinergic neuron maintenance, NF-kB anti-inflammatory signaling, and HPA axis modulation.
Current status: FDA GRAS Notice 1124 clears the beta-glucan fraction as food-grade safe. LiverTox score E (unlikely cause of liver injury). Zero FAERS signal. A 2025 Frontiers in Toxicology 90-day rat study established NOAEL at 2,000 mg/kg/day with no genotoxicity. No FDA-approved drug indication. Sold legally as a dietary supplement globally under DSHEA and equivalent frameworks. The legitimate safety concern is not regulatory but community-driven: r/LionsManeRecovery documents approximately 25,000 members reporting a persistent sexual anhedonia and emotional blunting cluster never confirmed in the RCT literature.
Terminology
- NGF: Nerve Growth Factor. A neurotrophic protein that maintains cholinergic neuron survival and drives neurogenesis. Central to Alzheimer's pathology where NGF transport is deficient.
- BDNF: Brain-Derived Neurotrophic Factor. A related neurotrophin that supports synaptic plasticity and hippocampal neurogenesis.
- TrkA: Tropomyosin receptor kinase A. The high-affinity NGF receptor.
- MCI: Mild Cognitive Impairment. A clinical state between normal cognitive aging and dementia, diagnosable by HDS-R or MMSE criteria.
- MMSE: Mini-Mental State Examination. A 30-point cognitive screening tool.
- HDS-R: Hasegawa Dementia Scale - Revised. The Japanese cognitive screening instrument used in Mori 2009.
- CFS: Cognitive Function Scale. Primary endpoint in Mori 2009.
- CES-D: Center for Epidemiologic Studies Depression Scale. A 20-item self-report depression screener.
- ICI: Indefinite Complaints Index. A Japanese menopausal-symptom scale used in Nagano 2010.
- PSQI: Pittsburgh Sleep Quality Index. Self-report sleep-quality instrument.
- SCL-90: Symptom Checklist-90. A 90-item psychiatric symptom inventory.
- BBB: Blood-Brain Barrier. The selective endothelial barrier that restricts most molecules from entering the central nervous system.
- BMP: Bone Morphogenetic Protein. A signaling family involved in adult neurogenesis.
- DCX: Doublecortin. A microtubule-associated protein expressed in migrating newborn neurons; a standard marker for hippocampal neurogenesis.
- NF-kB: Nuclear Factor kappa B. A master transcription factor for inflammation.
- COX-2: Cyclooxygenase-2. An inducible enzyme in prostaglandin synthesis and inflammation.
- HPA axis: Hypothalamic-Pituitary-Adrenal axis. The body's stress-response system.
- GRAS: Generally Recognized As Safe. FDA designation for food ingredients with expert-consensus safety.
- FAERS: FDA Adverse Event Reporting System. Public post-market surveillance database.
- NOAEL: No Observed Adverse Effect Level. The highest tested dose with no adverse findings in a toxicology study.
- PFS / PSSD: Post-Finasteride Syndrome and Post-SSRI Sexual Dysfunction. Persistent adverse syndromes the r/LionsManeRecovery community explicitly parallels.
- 5-AR: 5-alpha Reductase. The enzyme that converts testosterone to DHT. Finasteride's target.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 5 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | fruiting body 8:1 extract capsule | 1.8-3.2 g/day split 2x with food | 500 mg-3 g/day |
| oral | fruiting body powder | 2-3 g/day | 1-5 g/day |
| oral | erinacine-standardized mycelium | 500 mg-1.2 g/day | 500 mg-1.5 g/day |
| oral | dual-extraction tincture | 2-4 mL/day | 1-5 mL/day |
| culinary | whole fresh fruiting body | 5-20 g/serving | Stamets-endorsed |
Protocols
MCI / Aging Cognition (Mori 2009 Protocol) Clinical
- Dose
- 3 g/day fruiting body extract
- Frequency
- Daily split 2-3x with food
- Cycling
- Continuous for MCI population; washout documented
- Duration
- 16+ weeks; benefits revert within 4 weeks post-cessation
Matches Mori 2009 (CFS scores p<0.01 at weeks 8/12/16). Saitsu 2019 replicated at 3.2 g/day for 12 weeks
Healthy Adult Cognitive Enhancement Clinical
- Dose
- 1.8 g/day fruiting body extract
- Frequency
- Daily, morning with food
- Cycling
- Community default 5 on 2 off or 3 weeks on 1 off
- Duration
- 28+ days for working memory effect
Docherty 2023 at 1.8 g/day hit Stroop and spatial WM at d ~0.3-0.4 in n=41
Erinacine-Target Neurogenesis Mixed
- Dose
- 500 mg-1.2 g/day erinacine-standardized mycelium
- Frequency
- Daily
- Cycling
- Community default cycling applies
- Duration
- 8+ weeks
Ryu 2018 mouse hippocampal neurogenesis via erinacine A BMP pathway. Mycoforest, Erinamax
Menopausal Mood (Nagano 2010 Protocol) Clinical
- Dose
- 2 g/day fruiting body equivalent
- Frequency
- Daily
- Cycling
- Continuous short-term
- Duration
- 4 weeks minimum
Nagano 2010 n=30 menopausal women: CES-D + ICI reductions p<0.05. HPA-mechanism, not serotonergic
Post-Injury Nerve Recovery Anecdotal
- Dose
- 3-5 g/day fruiting body extract
- Frequency
- Split 2-3x daily
- Cycling
- Continuous during recovery window
- Duration
- 8-12 weeks
Based on Wong 2012 rat sciatic crush data. Community reports in concussion, Bell's palsy, peripheral neuropathy. Not RCT-validated in humans
Stamets Stack (Psilocybin Microdose Integration) Anecdotal
- Dose
- Lion's Mane 1-3 g + psilocybin microdose + niacin 25-200 mg
- Frequency
- 4 days on, 3 days off
- Cycling
- 4 active / 3 integration (Stamets protocol)
- Duration
- Ongoing cycles
Joe Rogan Experience #1035 (2017). Niacin vasodilation theoretically drives compounds into neural extremities. No formal evidence
How this score is calculated →
Upside (1.81 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 2.8 | 0.700 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 3.2 | 0.480 | |
| Total | 2.805 |
Upside Rationale
Efficacy (2.8/5.0): Effect sizes are moderate in cognitively impaired and older populations and smaller in healthy young adults. Mori et al. 2009 (MCI RCT, n=30, 3 g/day fruiting body for 16 weeks) improved Cognitive Function Scale scores at weeks 8, 12, and 16 at p<0.01, with estimated Cohen's d of 0.5 to 0.7, and is the only published RCT with a washout arm, where scores reverted within 4 weeks of cessation. Saitsu 2019 (n=31, 3.2 g/day for 12 weeks) replicated MMSE and Stroop improvements at p<0.05. Docherty 2023 (n=41 healthy young adults, 1.8 g/day for 28 days) found Stroop and spatial working memory improvements at d approximately 0.3 to 0.4, the low end of meaningful. Nagano 2010 (n=30 menopausal women, 2 g/day for 4 weeks) cut CES-D depression and Indefinite Complaints Index scores at p<0.05 through HPA modulation, not serotonergic pathways. Vigna 2019 (n=77 overweight adults, 400 mg/day for 8 weeks) improved SCL-90 psychiatric symptoms and PSQI sleep quality and raised pro-BDNF at p<0.01. None of the trials exceed n=77, and no independent replication of the Mori washout finding exists.
Breadth of Benefits (3.5/5.0): Lion's Mane spans cognition and memory (MCI, aging, healthy young adults), mood and mild depression (menopausal Nagano 2010; overweight Vigna 2019), peripheral nerve regeneration (Wong 2012 rat sciatic crush; Chang 2005 erinacine A myelination), myelin repair, gut (anti-H. pylori activity via Wang 2015; DSS colitis protection via Shang 2022; tight junction preservation), immune modulation (beta-glucan Th1/Th2, FDA GRAS Notice 1124), and antioxidant / anti-inflammatory effects (NF-kB inhibition, COX-2 downregulation, Nrf2 activation per Chang 2016). This is a true multi-system intervention, which is why the breadth dimension lands at 3.5 despite modest per-system effect sizes.
Evidence Quality (2.8/5.0): The human evidence base is four small RCTs (Mori 2009 n=30, Saitsu 2019 n=31, Nagano 2010 n=30, Docherty 2023 n=41) plus one larger overweight-cohort trial (Vigna 2019 n=77) and one unpublished 12-month Taiwan pilot at n=41. No systematic review or meta-analysis exists, and no Cochrane review covers any Lion's Mane indication. Mechanistic and rodent data is extensive (Ryu 2018 BBB-crossing erinacine A neurogenesis; Tsai-Teng 2016 APP/PS1 Alzheimer model; Wong 2012 nerve regeneration; Ratto 2019 frail aging mouse). Centuries of East Asian medicinal use adds tier-5 evidence. Penalties: all RCTs underpowered, most Japanese sites funded partly by Hokkaido Maitake (inconsistent disclosure), the longest trial is 16 weeks, and the washout finding has never been independently replicated.
Speed of Onset (2.5/5.0): Subjective effects emerge in 1 to 2 weeks per r/Nootropics community reports, with vivid dreams often the earliest marker. Measurable RCT endpoints appear at weeks 4 to 8: Nagano 2010 hit CES-D and ICI at 4 weeks, Mori 2009 significance appeared at week 8 and continued through 16. Docherty 2023 found acute Stroop improvement at 60 minutes post-dose, suggesting some effects are fast while neurotrophic rebuild is chronic. Not a fast-acting compound overall.
Durability (1.5/5.0): The Mori 2009 washout data is the most honest signal in the literature. Cognitive Function Scale scores reverted toward baseline within 4 weeks of cessation. This is mechanistically consistent: Lion's Mane provides ongoing NGF/BDNF support rather than installing permanent structural change. Stop taking it, lose the effect. No study has demonstrated persistent benefit after long-term discontinuation. This is the weakest upside dimension and a structural feature of the NGF-maintenance mechanism.
Bioindividuality Upside (3.2/5.0): Responder prediction is moderately tractable. MCI patients, aging populations (50+), creative workers in focus cycles, post-concussion or Bell's palsy recovery, and menopausal women with low-grade depressive symptoms respond most consistently. Healthy high-functioning young adults see smaller effects (Docherty 2023 d ~0.3-0.4). A minority report flat or negative experiences, including the sexual anhedonia cluster detailed in the downside section. Theoretical SNP predictors (SRD5A1/SRD5A2 for anhedonia susceptibility; ApoE4 for NGF-deficient responder profile) have not been clinically tested.
Downside (1.00 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.2 | 0.660 | |
| Side Effect Profile | 15% | 2.3 | 0.345 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 1.3 | 0.065 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.730 | |||
| Harm subtotal × 1.4 | 2.142 | |||
| Opportunity subtotal × 1.0 | 0.200 | |||
| Combined downside | 2.342 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.002 |
Downside Rationale
Safety Risk (2.2/5.0): Formal toxicology is excellent. LiverTox score E (unlikely cause of liver injury), zero FAERS signal, NOAEL at 2,000 mg/kg/day in a 2025 Frontiers in Toxicology 90-day rat study with no genotoxicity, FDA GRAS Notice 1124 for the beta-glucan fraction. RCT adverse-event rates are placebo-equivalent across all five published trials. The unresolved concern is the r/LionsManeRecovery community signal. The subreddit has grown to approximately 25,000 members reporting persistent penile dysesthesia, sexual anhedonia (pleasure absent despite erectile function intact), libido collapse, emotional blunting, and general anhedonia. Onset clusters at weeks 3 to 4. Resolves within 2 to 4 weeks post-cessation for most, but a tail of cases reports 3 to 12+ months of persistence. Reports are dose-independent and brand-independent. Proposed mechanisms are community-speculated and unconfirmed: mild 5-alpha reductase inhibition analogous to finasteride's PFS mechanism, or kappa-opioid agonism via erinacine E producing dysphoria and anhedonia. PSSD Network lists Lion's Mane alongside finasteride and SSRIs. Calibration: r/finasteride_side has approximately 60,000 members for a drug with approximately 1.5% PFS incidence on the FDA label. The Lion's Mane signal is real at meaningful volume, but prevalence is not established and the mechanism has never been confirmed in a clinical study.
Side Effect Profile (2.3/5.0): Beyond the anhedonia cluster, published RCT adverse events are mild: GI upset in ~23% (Mori 2009, statistically indistinguishable from placebo's 20%), occasional mild skin rash in sensitive individuals, transient mood shifts in the first 1 to 2 weeks, and vivid dreams at bedtime doses above 2 g. One documented ARDS case in a 63-year-old Japanese male with untreated diabetes was attributed to hypersensitivity, not direct toxicity. One allergic contact dermatitis case confirms mushroom-allergy risk. Cumulative adverse-effect profile is mild except for the anhedonia cluster, which is why Side Effects is scored 2.3 rather than the 1.5 a purely-mild profile would earn.
Financial Cost (1.5/5.0): $20 to $40 per month buys quality fruiting body 8:1 extract from Real Mushrooms ($30 to $45/mo) or Host Defense ($25 to $40/mo), with Nammex-sourced private-label options running $20 to $35/mo. Mycelium-grown-on-grain products drop to $10 to $20/mo but deliver substantially reduced erinacines and hericenones per Beelman 2019 USDA analysis showing beta-glucan content below 5% versus 25 to 40% in quality fruiting body. Extract ratio drives price: 8:1 dual-extraction costs 2 to 3x a 1:1 raw powder. Imported Japanese Yamabushitake products carry a 30 to 50% premium. DIY whole-mushroom route runs approximately $8/lb fresh at Asian markets. Per v0.5 accessible-channel rule, scored at mid-tier fruiting-body pricing.
Time/Effort Burden (1.2/5.0): Mori 2009 clinical dosing runs 250 mg x 3 capsules x 3x/day for 2,250 mg total, or nine capsules daily split with meals. Typical community protocol is lighter: 1 to 3 g once daily as capsules, 2 to 5 minutes of friction including water. Powder or tea prep adds 10 minutes for those who prefer the ritual. Cycling defaults (5 days on, 2 off for receptor sensitivity per community norms; 3 weeks on, 1 off for chronic users) add marginal tracking but no meaningful time cost. Timing relative to meals matters: NGF/BDNF absorption literature suggests pairing with dietary fat. No injections, no devices, no labs. Capsule-based daily friction lands at 2 to 5 minutes total.
Opportunity Cost (1.3/5.0): Stacking status is clean with no documented antagonism at standard doses. Pairs well with cognition-adjacent nootropics (Alpha-GPC, citicoline, omega-3 DHA, creatine monohydrate, bacopa, L-theanine) and does not antagonize a typical longevity stack (NMN, rapamycin, metformin, resveratrol). Bioindividual NGF responders who already run neurotrophic interventions (exercise, intermittent fasting, omega-3s) may see diminishing marginal return. Mushroom-adaptogen stacking (reishi, cordyceps, chaga) is popular but uncoordinated, without RCT guidance on synergy. No documented pharmaceutical interaction at standard doses beyond theoretical platelet effects with anticoagulants. Zero-dollar alternative is whole-foods mushroom consumption (shiitake, maitake, enoki) sharing weaker but overlapping beta-glucan mechanisms.
Dependency / Withdrawal (1.0/5.0): Mori 2009, Nagano 2010, and Saitsu 2019 report zero adaptation signal across 4 to 16 weeks of continuous dosing, with no tolerance, no escalation, no rebound. NGF and BDNF signaling does not produce the receptor downregulation that characterizes serotonergic or opioid tolerance; the neurotrophin pathway is regenerative rather than compensatory. Lovell 2015 neurotrophin literature documents reversibility of NGF pathway modulation without lasting receptor adaptation. No withdrawal reports surface in community data including r/Nootropics and r/LionsManeRecovery; the anhedonia cluster is an adverse effect profile, not dependency. Comparison to SSRI discontinuation syndrome does not apply (different mechanism entirely). Functional purely: stop, and cognitive baseline returns within 4 weeks per the Mori washout arm.
Reversibility (1.5/5.0): Effects wash out in weeks for most users per the Mori 2009 4-week washout data. The anhedonia tail cases push this slightly above the floor: most users recover fully within a month, but a minority reports symptoms lasting 3 to 12 months, and PSSD Network catalogs rare permanent-symptom reports. Score reflects this minority risk, not the majority profile.
Verdict
✅ Best for: Adults with subjective cognitive decline, early MCI, or aging-related memory complaints, where the strongest human evidence lives (Mori 2009, Saitsu 2019). Adults recovering from chemo brain, concussion, or peripheral nerve injury (Wong 2012 mechanism + community signal). Menopausal women with low-grade depressive symptoms (Nagano 2010). Creative workers in sustained focus cycles. Users who buy verified fruiting body 8:1 dual-extract from Real Mushrooms or Nootropics Depot, or erinacine-standardized mycelium from Mycoforest, and who run cycled protocols (5 on / 2 off, or 3 weeks on / 1 off) rather than chronic continuous use. See our adaptogenic mushroom roundup for brand-level comparison and our Mason Bresett podcast episode for a mycologist's perspective on sourcing.
❌ Avoid if: You have active anhedonia, sexual dysfunction, emotional blunting, or a post-finasteride syndrome history. You plan years of continuous no-cycle use (the anhedonia signal clusters in chronic uninterrupted dosing). You are buying mycelium-on-grain products (Four Sigmatic older lines, Om, most Amazon no-name brands), which can be 50 to 70% starch filler with beta-glucan content below 5% versus 25 to 40% in quality fruiting body extracts. You are on SSRIs, finasteride, or other agents with overlapping sexual side-effect profiles (stacking risk is theoretical but prudent). You have active mushroom allergy, end-stage renal disease on lithium, or are pregnant or nursing without clinician guidance.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 💪 Cognition / Focus | 7.0 | Mori 2009 MCI washout RCT d ~0.5-0.7; Saitsu 2019 replication; Docherty 2023 healthy young d ~0.3-0.4; cholinergic maintenance mechanism |
| 👍 Memory | 6.8 | MCI and aging populations show clearest memory signal; hippocampal neurogenesis via erinacine A (Ryu 2018) |
| 👍 Geriatric / Aging Population | 6.8 | Strongest demographic. Mori 2009 MCI ages 50-80; Saitsu 2019 ages 50-80; Ratto 2019 frail mouse aging model |
| 👍 Neuroprotection | 6.5 | Erinacine A BBB-crossing NGF induction; Tsai-Teng 2016 APP/PS1 Alzheimer mouse amyloid reduction |
| 👍 Nerve Regeneration | 6.5 | Wong 2012 rat sciatic crush; Chang 2005 erinacine A myelination; Kolotushkina 2003; strong preclinical |
| 👍 Mood / Emotional Regulation | 6.0 | Nagano 2010 menopausal CES-D reduction p<0.05; Vigna 2019 SCL-90 improvement; HPA mechanism not serotonergic |
| 👍 Neuroplasticity | 6.0 | Direct NGF/BDNF/TrkA signaling; pro-BDNF elevation documented (Vigna 2019 p<0.01) |
| 👍 Creativity / Divergent Thinking | 6.0 | Consistent Longecity/r/Nootropics anecdotal creativity reports; verbal fluency signal |
| ⚖️ Gut Health / Microbiome | 5.5 | Anti-H. pylori activity (Wang 2015); DSS colitis protection in mice (Shang 2022); tight junction support; no human RCTs |
| ⚖️ Immune Function | 5.5 | Beta-glucan Th1/Th2 modulation; FDA GRAS Notice 1124 covers beta-glucan fraction; moderate mechanistic base |
| ⚖️ Anxiety | 5.5 | Nagano 2010 ICI reduction in menopausal women; milder signal than depression |
| ⚖️ Anti-Inflammatory | 5.0 | NF-kB inhibition well-documented; COX-2 downregulation; mostly mechanistic |
| ⚖️ Antioxidant / Oxidative Stress | 5.0 | Polysaccharide and phenolic antioxidant activity; Nrf2 activation in vitro |
| ⚖️ Sleep Quality | 4.8 | Vigna 2019 PSQI improvement; community reports of vivid dreams; secondary endpoint only |
| ⚖️ Flow State / Peak Mental Performance | 4.8 | Anecdotal sustained-focus signal; cholinergic maintenance plausible; no RCT |
| ⚖️ Healthspan | 4.8 | Multi-system coverage (cognitive + immune + gut + nerve) but thin human data |
| ○ Stress / Resilience | 4.5 | HPA modulation mechanism; indirect evidence from mood RCTs |
| ○ Depression | 4.5 | Nagano 2010 + Vigna 2019 positive signal; underpowered; anhedonia risk complicates use case |
| ○ Injury Recovery | 4.5 | Community nerve-recovery signal (concussion, Bell's palsy); Wong 2012 mechanism; no human RCT |
| ○ Traumatic Brain Injury | 4.5 | Strong mechanistic rationale + community reports; no human TBI RCT |
| ○ Metabolic Health | 3.5 | Preliminary Taiwan prediabetic pilot (n=24) HbA1c -0.3%; unpublished; weak signal |
| ○ Sleep Architecture (Deep/REM) | 3.5 | Anecdotal vivid dreams (REM signal); no polysomnography data |
| ○ Recovery / Repair | 3.5 | Nerve-repair adjacent; anti-inflammatory mechanism; no clinical recovery RCT |
| ○ Energy / Fatigue | 3.5 | Indirect via anti-inflammatory and gut-brain axis; not a primary energy compound |
| ○ Blood Sugar / Glycemic Control | 3.0 | Animal STZ diabetic rat glucose reduction (Li 2014); no peer-reviewed human RCT |
| ○ Reaction Time / Coordination | 3.0 | Docherty 2023 Stroop acute signal at 60 min; limited |
| ○ Longevity / Lifespan | 3.0 | Indirect via neuroprotection + immune + gut; no lifespan RCT or large cohort |
Frequently Asked Questions
What does Lion's Mane actually do in the brain?
Lion's Mane contains two distinct bioactive families that converge on NGF and BDNF signaling per Ryu et al. 2018. Hericenones A through H live in the fruiting body and stimulate peripheral NGF synthesis via TrkA signaling. Erinacines A through K are concentrated in the mycelium, and erinacine A crosses the blood-brain barrier in rodent models to drive hippocampal neurogenesis through the BMP pathway. Downstream effects include cholinergic neuron maintenance, NF-kB anti-inflammatory signaling, myelin repair in crush-injury models (Wong 2012), and HPA axis modulation for mood. The fruiting body and mycelium reach the same NGF endpoint by different routes, which is why the form debate matters.
How much Lion's Mane should I take and which form?
Clinical range is 1.8 to 3.2 g/day of fruiting body extract split with food, matching Mori 2009 (3 g/day) and Saitsu 2019 (3.2 g/day). A beta-glucan standardized 8:1 fruiting body extract at 25 to 40% beta-glucan is the default format; erinacine-standardized mycelium at 500 mg to 1.2 g/day is the alternative when BBB-crossing neurogenesis is the goal. Community cycling protocols (5 days on 2 off, or 3 weeks on 1 off) are harm-reduction defaults given the r/LionsManeRecovery signal, not RCT-required. Avoid mycelium-on-grain products where beta-glucan content can drop below 5%.
Does Lion's Mane actually work for cognition in healthy adults?
Modest but real in young healthy adults; the larger signal lives in MCI and aging populations. Docherty et al. 2023 (n=41, 1.8 g/day for 28 days) found Stroop and spatial working memory improvements at Cohen's d approximately 0.3 to 0.4, the low end of meaningful. Mori 2009 in MCI (n=30, 3 g/day for 16 weeks) hit d approximately 0.5 to 0.7 with the important caveat that scores reverted within 4 weeks of cessation. Saitsu 2019 (n=31, 3.2 g/day for 12 weeks) replicated MMSE and Stroop improvements at p<0.05. No large powered RCT exists in either population, and no meta-analysis has been pooled.
Is Lion's Mane safe long-term?
Formal safety data is excellent but unresolved at the community signal. A 2025 Frontiers in Toxicology 90-day rat study established NOAEL at 2,000 mg/kg/day with no genotoxicity; LiverTox scores Lion's Mane E (unlikely cause of liver injury); FDA GRAS Notice 1124 covers the beta-glucan fraction; FAERS shows zero signal. The unsettled part is r/LionsManeRecovery, approximately 25,000 members reporting persistent sexual anhedonia, penile dysesthesia, libido collapse, and emotional blunting, typically onset at weeks 3 to 4, resolving in 2 to 4 weeks post-cessation for most but persisting 3 to 12+ months in a tail. Mechanism is community-speculated (5-alpha reductase inhibition or kappa-opioid agonism via erinacine E) and never clinically confirmed.
Who should avoid Lion's Mane?
Active sexual anhedonia, ED, or a post-finasteride syndrome (PFS) history should skip it outright given the r/LionsManeRecovery overlap and the proposed 5-alpha reductase mechanism. Concurrent SSRI use, finasteride, or other agents with overlapping sexual side-effect profiles warrant caution: the interaction is theoretical but the anhedonia cluster is not. Mushroom allergy is a hard contraindication after two documented hypersensitivity reactions. Pregnancy and lactation: precautionary avoid, no human RCTs. Anticoagulant users should monitor because hericenone B inhibits platelet aggregation in vitro. Immunosuppressed organ transplant patients: theoretical beta-glucan interference with immunosuppression.
Fruiting body vs mycelium: which form is legitimate?
Premium fruiting body 8:1 extract from Real Mushrooms or Nootropics Depot is the default, standardized to 25 to 40% beta-glucan and containing hericenones. Mycelium-on-grain products (most Amazon no-name, Four Sigmatic older lines, Om) can be 50 to 70% starch filler with beta-glucan content below 5% per independent lab analysis. The legitimate mycelium exception is erinacine-standardized bioreactor-grown mycelium (Nootropics Depot Erinamax, Mycoforest Taiwan) standardized to 0.5% erinacine A, which uniquely crosses the BBB per Ryu 2018. Paul Stamets uses a dual-extraction approach combining both. Community rule: 'If your product isn't bitter, it's probably oats.'
How long before Lion's Mane starts working?
Subjective effects emerge in 1 to 2 weeks per community reports, with vivid dreams often the earliest marker. Measurable RCT endpoints appear at weeks 4 to 8: Nagano 2010 hit CES-D depression and ICI anxiety reductions at 4 weeks (p<0.05) in menopausal women at 2 g/day. Mori 2009 significance appeared at week 8 in MCI, continued through weeks 12 and 16, and reverted within 4 weeks of cessation. Docherty 2023 found acute Stroop improvements at 60 minutes post-dose in healthy young adults, suggesting some effects are acute while neurotrophic rebuild is chronic. Not a fast-acting compound and not one-and-done.
Why is Hericium erinaceus different from cordyceps or reishi?
Hericium erinaceus is the only medicinal mushroom that produces hericenones and erinacines, the two NGF-stimulating compound families. Cordyceps delivers cordycepin and adenosine analogs for ATP/mitochondrial support. Reishi (Ganoderma lucidum) delivers triterpenes and beta-glucans for immune modulation and mild sedation. Reishi carries rare hepatotoxicity signals at very high doses that Lion's Mane lacks. Lion's Mane's species specificity matters because the closely related Hericium ramosum has been confused with H. erinaceus in at least one anti-androgen study often misattributed to H. erinaceus, a common source of contradictory mechanism claims in popular coverage.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension changes | New score |
|---|---|---|
| Powered RCT (n>200) replicates Mori 2009 in MCI at d>0.6 | Efficacy 2.8→3.5, Evidence 2.8→3.5 | 7.4 / 10 💪 Strong recommend |
| Case-control study confirms r/LionsManeRecovery signal with biological mechanism identified | Safety 2.2→3.5, Reversibility 1.5→2.8 | 5.4 / 10 ⚖️ Neutral |
| Case-control study refutes the anhedonia signal (confirms nocebo/community cluster) | Safety 2.2→1.5, Side Effects 2.3→1.5 | 7.1 / 10 💪 Strong recommend |
| 5-alpha reductase inhibition confirmed in human study at standard clinical doses | Safety 2.2→3.8, Reversibility 1.5→3.0, Side Effects 2.3→3.0 | 4.8 / 10 ⚖️ Neutral |
| Large prospective cohort (n>1,000) shows zero anhedonia excess vs controls at 2 years | Safety 2.2→1.5, Evidence 2.8→3.5, Durability 1.5→2.0 | 7.5 / 10 💪 Strong recommend |
| Alzheimer's phase 2/3 trial shows disease modification | Efficacy 2.8→3.8, Breadth 3.5→4.2, Evidence 2.8→3.8 | 7.9 / 10 💪 Strong recommend |
| First meta-analysis pools 6+ MCI RCTs with positive effect | Evidence 2.8→3.5 | 6.9 / 10 👍 Worth trying |
Key Evidence Sources
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. 2009, Phytotherapy Research. Improving effects of the mushroom Yamabushitake on mild cognitive impairment: double-blind placebo-controlled RCT. n=30 MCI adults ages 50-80; 3 g/day fruiting body powder for 16 weeks. Cognitive Function Scale scores improved at weeks 8, 12, 16 (p<0.01). Scores reverted by week 20 (4-week washout).. Only RCT with a washout arm. Anchor for Efficacy, Durability, and the reversion finding
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. 2019, Biomedical Research. Improvement of cognitive functions by oral intake of Hericium erinaceus. n=31 older adults; 3.2 g/day for 12 weeks. MMSE and Stroop improvements (p<0.05). Partial replication of Mori 2009 in a different population.. Partial replication of Mori; no washout arm
- Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. 2010, Biomedical Research. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. n=30 menopausal women; 2 g/day for 4 weeks. CES-D and Indefinite Complaints Index reduced (p<0.05). HPA mechanism hypothesized; not serotonergic.. Mood/anxiety RCT in menopausal women. Non-serotonergic mechanism signal
- Vigna L, Morelli F, Agnelli GM et al. 2019, Evidence-Based Complementary and Alternative Medicine. Hericium erinaceus improves mood and sleep disorders in overweight/obese patients. n=77; 400 mg/day for 8 weeks. SCL-90 depression/anxiety/somatization improved. PSQI improved. Pro-BDNF significantly increased (p<0.01).. Largest human Lion's Mane RCT to date. BDNF biomarker
- Docherty S, Doughty FL, Smith EF. 2023, Nutrients. The acute and chronic effects of Lion's Mane mushroom supplementation on cognitive function, stress and mood in young adults: double-blind pilot. n=41; 1.8 g/day for 28 days. Stroop at 60 min post-acute (p=0.038); spatial working memory at 28 days (p=0.049). d ~0.3-0.4.. Healthy young adult RCT. Small but statistically significant cognitive benefit
- Ryu S, Kim HG, Kim JY, Chung SY, Cho JH. 2018, Biomedicine & Pharmacotherapy. Hericium erinaceus extract reduces anxiety and depressive behaviors via erinacine A-BMP-hippocampal neurogenesis pathway. Mouse study. Confirms erinacine A BBB crossing and hippocampal dentate gyrus DCX+ cell proliferation.. Mechanism paper for erinacine A BBB crossing + neurogenesis
- Tsai-Teng T, Chin-Chu C, Li-Ya L et al. 2016, Journal of Biomedical Science. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease pathologies in APP/PS1 transgenic mice. Reduced amyloid plaque burden, improved spatial learning, increased hippocampal NGF.. Standard AD mouse model efficacy. Anchors neuroprotection subrating
- Wong KH, Naidu M, David P, Abdulla MA, Abdullah N, Kuppusamy UR, Sabaratnam V. 2012, Evidence-Based Complementary and Alternative Medicine. Peripheral nerve regeneration in rat peroneal crush injury by Hericium erinaceus aqueous extract. Accelerated functional recovery.. Primary rat nerve regeneration citation. Anchors nerve-regeneration subrating
- Ratto D, Corana F, Mannucci B et al. 2019, Nutrients. Hericium erinaceus improves recognition memory and induces hippocampal and cerebellar neurogenesis in frail mice during aging. Narrative-review + frail mouse neurogenesis data.. Frail aging mouse model; supports geriatric subrating
- Frontiers in Toxicology 2025. Toxicological assessment of Hericium erinaceus and Trametes versicolor powders. 90-day rat oral toxicity study: NOAEL ≥ 2,000 mg/kg/day. No genotoxicity in bacterial or in vivo micronucleus assays.. Anchor for formal safety
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Hericium erinaceus monograph. NIH/NIDDK. Likelihood score E: unlikely cause of liver injury. Zero serum enzyme elevations across trials.. Liver safety authority
- FDA GRAS Notice 1124 - Lion's Mane Beta-Glucan. Generally Recognized As Safe determination for the beta-glucan fraction of Hericium erinaceus.. Regulatory clearance for the beta-glucan fraction
- r/LionsManeRecovery community. ~25,000 members reporting persistent penile dysesthesia, sexual anhedonia, libido collapse, emotional blunting. Onset weeks 3-4; resolves 2-4 weeks post-cessation for most; 3-12+ month tail in minority. Mechanism unconfirmed: community-speculated 5-alpha reductase inhibition or kappa-opioid agonism via erinacine E.. Primary adversarial community signal. Tier-6 anecdotal but volume is material
- Kawagishi H, Shimada A, Shirai R et al. 1994, Tetrahedron Letters. Erinacines A, B and C, strong stimulators of NGF synthesis, from the mycelia of Hericium erinaceum. Original isolation of the erinacine family.. Original erinacine isolation paper
- Chang HC, Yang HL, Pan JH et al. 2016, Oxidative Medicine and Cellular Longevity. Hericium erinaceus Nrf2/NF-kB modulation in endothelial cells. Anti-inflammatory and antioxidant mechanism.. NF-kB / Nrf2 mechanism paper
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.805 − 1.002 = 0.803
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((0.803 + 7) / 12) × 10 = 6.5 / 10
Further reading
Ultimate Guide to Adaptogenic Mushrooms: Everything You MUST Know
This is ancient secret of adaptogenic mushroom supplements. We discuss key health benefits like naturally enhanced immunity, boosted brain function, and reduced stress levels.…
Science of Medicinal Mushrooms, Adaptogens, & Herbs
Mushrooms aren't just for your stir-fry—they're potent adaptogens. In this episode, Dr. Mason Bresett, Chief Science Advisor at Real Mushrooms, delves into the therapeutic…
